N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide is an aldehyde-functionalized ADC linker that enables selective conjugation to antibodies, optimizing payload stability and targeted antibody-drug conjugate delivery.
Structure of 1226200-04-9
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide has attracted attention in the field of pharmaceutical research due to its distinct molecular structure and potential for various medical applications. The incorporation of both chlorophenoxy and formylbenzamide groups into its framework allows for unique interactions with biological targets, paving the way for its evaluation as a novel therapeutic agent. Scientists are particularly interested in exploring its effectiveness and safety across a range of diseases, offering hope for new treatment modalities that address both efficacy and safety challenges commonly faced in drug development.
One significant application of N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide is in the realm of cancer therapeutics. Researchers are investigating its capability to act as an anti-cancer agent through mechanisms such as inhibition of cancer cell proliferation and induction of apoptosis. Its selective activity against malignant cells suggests it has the potential for development into a targeted therapy, which could result in fewer side effects compared to traditional chemotherapeutic agents. This focus on reducing collateral damage to healthy cells is critical in improving the quality of life for cancer patients and enhancing the overall effectiveness of cancer treatment regimens.
In addition to its potential in oncology, N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide is being studied for its anti-inflammatory capabilities. Its structural properties allow it to modulate key inflammatory pathways, making it a promising candidate for the treatment of inflammatory conditions such as Crohn's disease and ulcerative colitis. By potentially reducing the overactive inflammatory responses that characterize these diseases, the compound could help alleviate symptoms and prevent long-term tissue damage. Researchers are actively conducting studies to better understand its mechanism of action and therapeutic potential in chronic inflammatory diseases.
Moreover, the compound holds promise in neurological applications, particularly in offering neuroprotection. Diseases like Alzheimer's and Parkinson's are characterized by progressive neuronal damage, and compounds that can protect nerve cells are of immense interest. N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide is being evaluated for its ability to support neuronal health and function, thereby possibly decelerating disease progression. The focus on neuroprotective properties is part of broader efforts to develop medications that not only manage symptoms but also address underlying disease mechanisms, potentially leading to breakthroughs in how neurodegenerative diseases are treated. This comprehensive approach highlights the compound's versatility and its importance in the pursuit of innovative therapies for complex diseases.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00523 | N-(2-(2-Chloroethoxy)ethyl)-4-Formylbenzamide | 1137575-49-5 | |
BADC-00531 | N-(2-(4-Fluorophenoxy)ethyl)-4-Formylbenzamide | 1225588-22-6 | |
BADC-00532 | N-(2-(3-Fluorophenoxy)ethyl)-4-Formylbenzamide | 1225588-29-3 | |
BADC-00533 | N-(2-(2-Fluorophenoxy)ethyl)-4-Formylbenzamide | 1225705-45-2 | |
BADC-00534 | N-(2-(3-Ethylphenoxy)ethyl)-4-Formylbenzamide | 1225790-49-7 | |
BADC-00535 | N-(2-(4-Ethylphenoxy)ethyl)-4-Formylbenzamide | 1225790-59-9 | |
BADC-00536 | N-(2-(2,6-Dimethylphenoxy)ethyl)-4-Formylbenzamide | 1225936-91-3 | |
BADC-00539 | N-(2-(2-Chlorophenoxy)ethyl)-4-Formylbenzamide | 1225972-65-5 | |
BADC-00540 | N-(2-((2,3-Dihydro-1H-Inden-5-yl)oxy)ethyl)-4-Formylbenzamide | 1225979-81-6 | |
BADC-00541 | N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide | 1226006-03-6 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.